title: Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients.
abstract: OBJECTIVE
  To study the clinical spectrum and evolution of Churg-Strauss syndrome in order to assess the clinicopathological features of the disease, the response to treatment and the long-term outcome.
  
  
  METHODS
  Thirty-two patients with proven allergic and granulomatous angiitis (Churg-Strauss syndrome) and followed up at a single institution were evaluated. They were recruited between 1977 and 1999 from internal medicine departments. Data were obtained retrospectively from medical files in 15 cases and prospectively, using a standardized form, for the remaining patients.
  
  
  RESULTS
  All patients had asthma and hypereosinophilia. The lungs, skin and peripheral nervous system were the organs most frequently involved. Antineutrophil cytoplasmic antibodies with antimyeloperoxidase specificity (MPO-ANCA) were detected in 77.8% of tested patients but they were not useful for monitoring disease activity. Extravascular granulomas were rarely seen in tissue biopsies. Forty per cent of the patients were treated with steroids alone. Immunosuppressive agents were added to the treatment when severe neurological, cardiac or gastrointestinal involvement was present. The outcome and long-term survival were good. Clinical relapse was rare after the first year of therapy. Dysaesthesiae of the distal limbs, neurophatic pain and cardiac failure were the most frequent sequelae.
  
  
  CONCLUSIONS
  Churg-Strauss syndrome is a rare disorder characterized by hypereosinophilia and systemic vasculitis occurring in patients with asthma and allergic rhinitis. Vasculitis commonly affects the lungs, skin and peripheral nervous system. Outcome and long-term survival is usually good with steroids alone or in combination with immunosuppressive agents. The syndrome has a low mortality rate compared with other systemic vasculitides.
authors.affiliation: Department of Internal Medicine, Department of Pathology, Department of Pneumology and. Department of Preventive Medicine, Vall d'Hebrón University General Hospital, 08035 Barcelona, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Solans
authors.forename: J A
authors.initials: JA
authors.lastname: Bosch
authors.forename: C
authors.initials: C
authors.lastname: Pérez-Bocanegra
authors.forename: A
authors.initials: A
authors.lastname: Selva
authors.forename: P
authors.initials: P
authors.lastname: Huguet
authors.forename: J
authors.initials: J
authors.lastname: Alijotas
authors.forename: R
authors.initials: R
authors.lastname: Orriols
authors.forename: L
authors.initials: L
authors.lastname: Armadans
authors.forename: M
authors.initials: M
authors.lastname: Vilardell
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001249:Asthma / Q000209:etiology / Q000473:pathology; D001379:Azathioprine / Q000627:therapeutic use; D015267:Churg-Strauss Syndrome / Q000150:complications / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004802:Eosinophilia / Q000209:etiology / Q000473:pathology; D005260:Female; D006785:Hospitals, University; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D013030:Spain; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D001379:Azathioprine; D011241:Prednisone